TB-500 research is rooted in Thymosin Beta-4 science spanning several decades
Always work with a licensed medical provider, never with unregulated online vendors
Chemistry alone wont be enough
Treatment is subject to a pharmacist suitability assessment
Explored as a possible aid for recovery and lean-mass preservation in frail or catabolic populations, though a Merck-sponsored Phase 2b trial in elderly hip-fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics, PMID 21067829) was halted early over a cardiac safety signal rather than demonstrating a clear functional benefit
FDA Accepts Atara Biotherapeutics Resubmission of BLA for Tabelecleucel January 5, 2026 Ultragenyx has completed its submission of a rolling BLA to the FDA for DTX401, an investigational AAV serotype 8 (AAV8) vector gene therapy expressing the human G6PC gene that is intended to treat Glycogen Storage Disease Type Ia (GSDIa)